UroGen Pharma is pushing cancer care out of the hospital and into the urologist’s office, with a new treatment that aims to reduce repeat surgeries as doctors and payers look for less invasive options. The big question is whether insurance access and the company’s heavy spending ease fast enough for the launch to turn into lasting growth instead of more funding needs.Read more
UroGen is betting that urologists will quickly switch more patients from surgery to its newer bladder cancer treatments as payment rules get simpler, which could make sales grow faster than many expect. But the company is still losing money and leans on just two products while bigger rivals crowd the space.Read more
UroGen Pharma’s growth story hinges on new bladder-cancer treatments, but tougher drug oversight and pricing pushback could slow launches and limit how widely its newest product is used. With so much depending on just a couple of medicines—and the need to keep raising money—small setbacks or faster-moving rivals could quickly change the outlook.Read more
No trending discussion available.
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
